Cargando…
Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
PURPOSE: Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC), including ground-glass opacity (GGO)-type lung cancer. However, some patients are inoperable or refuse to undergo surgery. To explore whether proton beam therapy (PBT) can be an alternative to surgical res...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553652/ https://www.ncbi.nlm.nih.gov/pubmed/33117018 http://dx.doi.org/10.2147/LCTT.S270283 |
_version_ | 1783593648766582784 |
---|---|
author | Nagata, Ichiro Ogino, Takashi Arimura, Takeshi Yoshiura, Takashi |
author_facet | Nagata, Ichiro Ogino, Takashi Arimura, Takeshi Yoshiura, Takashi |
author_sort | Nagata, Ichiro |
collection | PubMed |
description | PURPOSE: Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC), including ground-glass opacity (GGO)-type lung cancer. However, some patients are inoperable or refuse to undergo surgery. To explore whether proton beam therapy (PBT) can be an alternative to surgical resection in these patients, this study aimed to examine the retrospective treatment outcomes of patients with GGO-type lung cancer who underwent PBT. PATIENTS AND METHODS: Patients with stage I NSCLC and GGOs who underwent PBT at the Medipolis Proton Therapy and Research Center (Kagoshima, Japan) between April 2011 and September 2015 were included. Patients were treated with a total dose of 66 GyE delivered in 10 fractions. Survival curves were calculated using the Kaplan–Meier method, and treatment-related adverse events (AEs) were assessed. RESULTS: A total of 48 patients (median age: 70.9 ± 9.2 years; men: 54.2%) were analyzed, among whom 53 tumors were observed. The 3-year overall survival rate after PBT was 91.7% (95% confidence interval [CI], 79.3–96.8%), the 3-year disease-free survival rate was 85.4% (95% CI: 71.8–92.8%), and the 3-year local control rate among 53 tumors was 92.5% (95% CI: 81.1–97.1%). During the 3-year follow-up period, 4 patients died, and 3 survived despite recurrence or metastasis. Common AEs were radiation pneumonitis (89.6%), rib fracture (27.1%), and cough (27.1%). None of the patients developed grade ≥3 treatment-related AEs. CONCLUSION: The results of this study suggest that PBT may be a promising alternative for patients with GGO-type lung cancer when surgical resection is not feasible, with excellent survival outcomes and tolerable treatment-related AEs. |
format | Online Article Text |
id | pubmed-7553652 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-75536522020-10-27 Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer Nagata, Ichiro Ogino, Takashi Arimura, Takeshi Yoshiura, Takashi Lung Cancer (Auckl) Original Research PURPOSE: Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC), including ground-glass opacity (GGO)-type lung cancer. However, some patients are inoperable or refuse to undergo surgery. To explore whether proton beam therapy (PBT) can be an alternative to surgical resection in these patients, this study aimed to examine the retrospective treatment outcomes of patients with GGO-type lung cancer who underwent PBT. PATIENTS AND METHODS: Patients with stage I NSCLC and GGOs who underwent PBT at the Medipolis Proton Therapy and Research Center (Kagoshima, Japan) between April 2011 and September 2015 were included. Patients were treated with a total dose of 66 GyE delivered in 10 fractions. Survival curves were calculated using the Kaplan–Meier method, and treatment-related adverse events (AEs) were assessed. RESULTS: A total of 48 patients (median age: 70.9 ± 9.2 years; men: 54.2%) were analyzed, among whom 53 tumors were observed. The 3-year overall survival rate after PBT was 91.7% (95% confidence interval [CI], 79.3–96.8%), the 3-year disease-free survival rate was 85.4% (95% CI: 71.8–92.8%), and the 3-year local control rate among 53 tumors was 92.5% (95% CI: 81.1–97.1%). During the 3-year follow-up period, 4 patients died, and 3 survived despite recurrence or metastasis. Common AEs were radiation pneumonitis (89.6%), rib fracture (27.1%), and cough (27.1%). None of the patients developed grade ≥3 treatment-related AEs. CONCLUSION: The results of this study suggest that PBT may be a promising alternative for patients with GGO-type lung cancer when surgical resection is not feasible, with excellent survival outcomes and tolerable treatment-related AEs. Dove 2020-10-09 /pmc/articles/PMC7553652/ /pubmed/33117018 http://dx.doi.org/10.2147/LCTT.S270283 Text en © 2020 Nagata et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Nagata, Ichiro Ogino, Takashi Arimura, Takeshi Yoshiura, Takashi Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer |
title | Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer |
title_full | Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer |
title_fullStr | Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer |
title_full_unstemmed | Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer |
title_short | Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer |
title_sort | clinical outcomes of proton beam therapy for ground-glass opacity-type lung cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553652/ https://www.ncbi.nlm.nih.gov/pubmed/33117018 http://dx.doi.org/10.2147/LCTT.S270283 |
work_keys_str_mv | AT nagataichiro clinicaloutcomesofprotonbeamtherapyforgroundglassopacitytypelungcancer AT oginotakashi clinicaloutcomesofprotonbeamtherapyforgroundglassopacitytypelungcancer AT arimuratakeshi clinicaloutcomesofprotonbeamtherapyforgroundglassopacitytypelungcancer AT yoshiuratakashi clinicaloutcomesofprotonbeamtherapyforgroundglassopacitytypelungcancer |